View live charts, options flow & technicals for Zimmer Biomet Holdings, Inc. →
Open Dashboard
Zimmer Biomet Holdings, Inc. (ZBH) is a healthcare company in the medical devices industry with $8.51B in trailing revenue trading at a 22.1× trailing P/E — analyst consensus: buy.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Key Statistics
Market Cap
$17.33B
Revenue (TTM)
$8.51B
EPS (TTM)
$4.12
EPS (Fwd est.)
$9.07
Employees
17,000
Trailing P/E
22.06
Forward P/E
10.02
PEG Ratio
0.59
Price / Sales
2.04
Price / Book
1.37
EV / EBITDA
9.70
Beta (5Y)
0.47
Analyst Consensus
Consensus
Buy
Analyst Price Target
+18.4% upside
Target: $107.57
Annual Revenue & Net Income
RevenueNet Income
'22
$6.94B
$230.00M
'23
$7.39B
$1.02B
'24
$7.68B
$900.00M
'25
$8.23B
$710.00M
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$2.07
$2.01
Beat (+3.0%)
Apr 2026
$2.09
$1.86
Beat (+12.2%)
Feb 2026
$2.42
$2.40
Beat (+0.9%)
Nov 2025
$1.90
$1.87
Beat (+1.8%)
Next Earnings Report
Zimmer Biomet Holdings, Inc. is next expected to report earnings on 05 Nov 2026.
Profitability
69.5%
18.0%
9.5%
Gross MarginOperating MarginNet Margin
Revenue Growth (YoY)
4.8%
Return on Equity
6.4%
Return on Assets
3.9%
Balance Sheet
Cash & Equivalents
$460.00M
Total Debt
$7.60B
Net Position
$7.14B (net debt)
Free Cash Flow (TTM)
$1.07B
Debt / Equity
60.17
Share Ownership
Institutions 111.4%
Insiders 0.2%
Institutional figure exceeds 100% due to short selling
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tiss…
What is ZBH's market cap?
Zimmer Biomet Holdings, Inc. has a market capitalization of approximately $17.33B.
What is ZBH's P/E ratio?
Zimmer Biomet Holdings, Inc. trades at a trailing P/E ratio of 22.1x and a forward P/E of 10.0x, which is below the broad market average of ~25x.
How much revenue does ZBH generate?
Zimmer Biomet Holdings, Inc. generated $8.51B in trailing 12-month revenue.
What do analysts say about ZBH?
The analyst consensus rating for Zimmer Biomet Holdings, Inc. is buy, with a mean price target of $107.57. That implies +18.4% upside from the current price.
When does ZBH report earnings?
Zimmer Biomet Holdings, Inc. is next scheduled to report earnings on 05 Nov 2026.
Does ZBH pay a dividend?
Yes. Zimmer Biomet Holdings, Inc. pays a dividend with a current yield of 1.02%, at an annual rate of $0.96 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Zimmer Biomet Holdings, Inc. on Apsis Markets.